Ratings Nutex Health Inc.

Equities

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
0.647 ^USD	+6.24%		+0.47%	-76.04%

May. 09	Earnings Flash (NUTX) NUTEX HEALTH Posts Q1 Revenue $67.5M	MT
May. 09	Nutex Health Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by -100% by 2026.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

	1st Jan change	Capi.	ESG Refinitiv
NUTEX HEALTH INC.	-76.04%	32.71M	-
HCA HEALTHCARE, INC.	+18.92%	84.31B	C+
CVS HEALTH CORPORATION	-29.48%	69.9B	B-
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+9.65%	29.06B	C+
FRESENIUS SE & CO. KGAA	+2.14%	17.01B	A-
LABORATORY CORPORATION OF AMERICA HOLDINGS	-9.30%	17.38B	B
QUEST DIAGNOSTICS INCORPORATED	+0.20%	15.35B	A-
REDE D'OR SÃO LUIZ S.A.	+5.25%	12.91B	B-
TENET HEALTHCARE CORPORATION	+68.96%	12.47B	C+
EUROFINS SCIENTIFIC SE	-2.24%	11.9B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality